Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266100, China.
Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China.
Angew Chem Int Ed Engl. 2024 Oct 21;63(43):e202405860. doi: 10.1002/anie.202405860. Epub 2024 Jul 17.
Numerous clinical disorders have been linked to the etiology of dysregulated NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome activation. Despite its potential as a pharmacological target, modulation of NLRP3 activity remains challenging. Only a sparse number of compounds have been reported that can modulate NLRP3 and none of them have been developed into a commercially available drug. In this research, we identified three potent NLRP3 inflammasome inhibitors, gymnoasins A-C (1-3), with unprecedented pentacyclic scaffolds, from an Antarctic fungus Pseudogymnoascus sp. HDN17-895, which represent the first naturally occurring naphthopyrone-macrolide hybrids. Additionally, biomimetic synthesis of gymnoasin A (1) was also achieved validating the chemical structure and affording ample amounts of material for exhaustive bioactivity assessments. Biological assays indicated that 1 could significantly inhibited in vitro NLRP3 inflammasome activation and in vivo pro-inflammatory cytokine IL-1β release, representing a valuable new lead compound for the development of novel therapeutics with the potential to inhibit the NLRP3 inflammasome.
已有大量临床疾病被认为与 NLRP3(NACHT、LRR 和 PYD 结构域包含蛋白 3)炎性小体激活的失调有关。尽管 NLRP3 作为药理学靶点具有很大的潜力,但调控其活性仍然具有挑战性。目前仅有少数几种能够调节 NLRP3 的化合物被报道,而且它们都没有被开发成商业上可用的药物。在这项研究中,我们从南极真菌 Pseudogymnoascus sp. HDN17-895 中发现了三种具有前所未有的五环骨架的强效 NLRP3 炎性小体抑制剂,gymnoasins A-C(1-3),它们代表了第一个天然存在的萘并吡喃酮-大环内酯类杂种。此外,还通过仿生合成获得了 gymnoasin A(1),验证了其化学结构,并提供了大量的材料进行全面的生物活性评估。生物测定表明,1 可显著抑制体外 NLRP3 炎性小体激活和体内促炎细胞因子 IL-1β 的释放,代表了一种有价值的新型先导化合物,可用于开发具有抑制 NLRP3 炎性小体潜力的新型治疗药物。